Chen Zhuo, Yi Xin, Fu Wei, Wu Yong, Zhong Xingju, Fan Chaoli, Jiang Yu, Zhou Qi, Peng Jie, Liao Jieyu, You Zhike, Tan Jingyu
Department of Neurology, Mianzhu People's Hospital, Mianzhu, Sichuan, China.
Department of Endocrinology, Mianzhu People's Hospital, Mianzhu, Sichuan, China.
Front Aging Neurosci. 2024 Nov 22;16:1463065. doi: 10.3389/fnagi.2024.1463065. eCollection 2024.
Triggering receptor expressed on myeloid cells-1 (TREM-1) was reported to be critical for mediating the neurological function after stroke, while the impact of soluble TREM-1 (sTREM-1) on cognitive impairment after ischemic stroke is unclear. We aimed to explore the association between sTREM-1 and post-stroke cognitive impairment (PSCI).
We prospectively recruited consecutive ischemic stroke patients who admitted hospital within 7 days of onset. Serum sTREM-1 concentrations were measured after admission. Cognitive function was assessed at 90 days follow-up using the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). PSCI was defined as a MMSE score of <27 or a MoCA score < 26.
A total of 291 patients (mean age, 66.6 years; 46.0% female) were enrolled for this study. Among these participants, the median sTREM-1 concentrations were 289.4 pg/mL. According to the MoCA score, 153 (52.6%) patients experienced PSCI at 3 months. After adjustment for confounding risk factors by multivariate regression analysis, patients with sTREM-1 levels in the fourth quartile were more likely to have increased risk 3-month PSCI (as compared with the first quartile, odds ratio 12.22, 95% confidence intervals, 5.20-28.71, = 0.001). Restricted cubic spline further confirmed a dose-dependent relationship between sTREM-1 levels and PSCI ( = 0.003 for linearity). Similar significant findings were observed when the cognitive impairment was diagnosed according to the MMSE criterion.
Our study revealed that higher serum sTREM-1 levels at admission were associated with increased risk of 3-month PSCI.
据报道，髓系细胞触发受体-1（TREM-1）对卒中后神经功能的介导至关重要，而可溶性TREM-1（sTREM-1）对缺血性卒中后认知障碍的影响尚不清楚。我们旨在探讨sTREM-1与卒中后认知障碍（PSCI）之间的关联。
我们前瞻性地招募了发病7天内入院的连续性缺血性卒中患者。入院后测定血清sTREM-1浓度。在90天随访时使用简易精神状态检查表（MMSE）和蒙特利尔认知评估量表（MoCA）评估认知功能。PSCI定义为MMSE评分<27或MoCA评分<26。
本研究共纳入291例患者（平均年龄66.6岁；46.0%为女性）。在这些参与者中，sTREM-1浓度中位数为289.4 pg/mL。根据MoCA评分，153例（52.6%）患者在3个月时发生PSCI。通过多因素回归分析调整混杂风险因素后，sTREM-1水平处于第四四分位数的患者发生3个月PSCI的风险更高（与第一四分位数相比，比值比为12.22，95%置信区间为5.20-28.71，P = 0.001）。受限立方样条进一步证实了sTREM-1水平与PSCI之间的剂量依赖关系（线性关系P = 0.003）。根据MMSE标准诊断认知障碍时，观察到类似的显著结果。
我们的研究表明，入院时较高的血清sTREM-1水平与3个月PSCI风险增加相关。
